Home › Trial NCT01203020
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
- Trial IDNCT01203020
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorWest Virginia University
- Enrollment22
- Start date2010-10-12
- ConditionsHodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.